-
264%
OncQuer(TM) MPN Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer(TM) MPN Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
265%
ONCQUER(TM) MRD PANEL
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerONCQUER(TM) MRD PANEL
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
265%
OncQuer(TM) MYD88 Mutation Tes ...
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer(TM) MYD88 Mutation Tes ...
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
265%
OncQuer(TM) Myeloid Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancerOncQuer(TM) Myeloid Panel
Identification of therapeutically relevant gene mutations for Myeloid cancerCancer -
272%
OncQuerTM Canassist Test
Identification of therapeutically relevant gene mutations for Cancer -
265%
OncQuerTM Focus Panel
Identification of therapeutically relevant gene mutations for Cancer -
272%
ONCQUERTM SARCOMA PANEL
Identification of therapeutically relevant gene mutations for Cancer - 265%
-
265%
Osmotic Fragillity Test
This assay is helpful in detecting or confirming mild spherocytosis and is used in suspected cases…Osmotic Fragillity Test
This assay is helpful in detecting or confirming mild spherocytosis and is used in suspected cases…
